Cancer - September 2014 Archives

JACKSONVILLE, Flórida 30 de setembro de 2014 — Análises em mais de 8 mil mulheres, que participaram do maior estudo mundial de dois medicamentos para o câncer de mama HER2-positivo, reforçam outras descobertas de estudos clínicos mostrando que o trastuzumabe (Herceptin) deve permanecer como o padrão de tratamento desse tipo de câncer, diz uma pesquisadora da Clínica Mayo.

ROCHESTER, Minn. ― Here are highlights from the September issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscription information as your editorial policies permit: Visit www.HealthLetter.MayoClinic.com or call toll-free for subscription information, 1-800-333-9037, extension 9771. Full newsletter text: Mayo Clinic Health Letter September 2014 (for journalists only). After celebrating, survivors often face anxieties and fear Adjusting from being a cancer patient to a cancer survivor isn't just about celebration and gratitude. The September issue of Mayo Clinic Health Letter covers why this transition isn’t always smooth or easy. In addition to dealing with fatigue or other side effects of surgery or treatment, patients may be surprised by feelings that can include fear and uncertainty, anxiety, sadness and irritability.

JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. http://youtu.be/BcFszcq4CJo

More than 8 of 10 say they would make same choice again, Mayo Clinic study finds ROCHESTER, Minn. — More women with cancer in one breast are opting to have both breasts removed to reduce their risk of future cancer. New research shows that in the long term, most have no regrets. Mayo Clinic surveyed hundreds of women with breast cancer who had double mastectomies between 1960 and 1993 and found that nearly all would make the same choice again. The findings are published in the journal Annals of Surgical Oncology. The study made a surprising finding: While most women were satisfied with their decision whether they followed it with breast reconstruction or not, patients who decided against reconstructive surgery were likelier to say they would choose to have both breasts removed again. In the reconstructive surgery group, women who needed additional operations due to complications, breast implant-related issues or other reasons were likelier to regret their prophylactic mastectomy, though overall, most women with breast reconstructions were satisfied with their choices. MEDIA CONTACT: Sharon Theimer, Mayo Clinic Public Affairs, 507-284-5005, Email: newsbureau@mayo.edu

Rochester, Minn. – Mayo Clinic announced today that it is part of a newly formed consortium, including experts from academic medical centers and commercial genetics laboratories across the country, that has established the Prospective Registry of Multi-Plex Testing (PROMPT), an online registry for individuals and families who have undergone testing for inherited cancer-causing genetic mutations. Co-founded by Mayo Clinic Cancer Center, Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Penn Medicine, the goal of the registry is to provide data vital to improving our understanding of the level of risk associated with and outcomes following testing for “panels” of cancer-associated genes. The consortium is now enrolling patients in the first phase of the study. “An enormous challenge in the practice of medicine today is that posed by panel testing of dozens of cancer genes, some of which are recently discovered and for which we do not have adequate information to guide preventive strategies,” said co-founder, Susan Domchek, M.D., director of the Basser Research Center for BRCA at the University of Pennsylvania’s Abramson Cancer Center. MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

DEAR MAYO CLINIC: I am 44 and in good health. Two weeks ago I became very ill (bloody diarrhea and severe abdominal cramping for three days) after eating at a restaurant. The stool samples did not show any sign of food-borne disease, and I was told my symptoms were probably the result of a virus. I am concerned that it could be something more serious. Should I request further testing? ANSWER: A variety of conditions could be the cause of your illness. If you no longer have any symptoms, then it is unlikely you need additional testing. If you are still having some symptoms, then more investigation is required. In someone who has previously been well, who has no history of gastrointestinal (GI) complaints and who has a bloody, diarrheal illness that comes on quickly, we can divide the likely possible causes into two main categories: infectious diarrhea versus inflammatory diarrhea.

Mayo Clinic Cancer Center and the American Association for Cancer Research host Twitter Chat   Mayo Clinic Cancer Center and the American Association for ...

THIS WEEK'S TOP STORIES Weight loss: Gain control of emotional eating Do you turn to food when you're stressed? Emotional eating can sabotage your weight-loss efforts. Here's how to get back on track. Prostate cancer prevention: Ways to reduce your risk There's no sure way to prevent prostate cancer. But you may lower your risk by exercising and adjusting your diet. Try these tips. PLUS ADDITIONAL HIGHLIGHTS Skin care: 5 tips for healthy skin Aging: What to expect Slide show: Aquatic exercises Fruit recipes EXPERT ANSWERS Ocular migraine: When to seek help An ocular migraine can mean one of two conditions. Learn which is more serious. Hepatitis C: How common is sexual transmission? Although hepatitis C is highly contagious, the risk of sexual transmission is very low. Click here to get a free e-subscription to the Housecall newsletter.

Groups offer support for brain tumor survivors If you have a brain tumor, finding information specific to its type is important. Here are support ...

According to the Centers for Disease Control and Prevention, more than 20,000 women in the U.S. are diagnosed with ovarian cancer each year. Most of them are over ...

JACKSONVILLE, Flórida, — Os médicos anteveem um futuro em que os dados do genoma de pacientes são bastante usados para gerir sua saúde — mas os especialistas questionam a precisão e a confiabilidade dessas análises. Agora, estudo realizado por 150 pesquisadores, em 12 países, verifica que há consistência e similares reais em técnicas e laboratórios de sequenciamento genômico de RNA, bem como em maneiras de corrigir pequenas variações existentes, para estabelecer um novo alto padrão. Os resultados do estudo foram publicados pelo periódico Nature Biotechnology, em três artigos sobre a pesquisa. “Os resultados devem oferecer uma certeza a pacientes, médicos e à comunidade de pesquisa de que o sequenciamento genômico é preciso”, diz o professor de biologia do câncer E. Aubrey Thompson, da Clínica Mayo da Flórida, uma das três instituições de saúde que lideraram o estudo. Thompson é um dos coautores do estudo e integrante da liderança do projeto.

THIS WEEK'S TOP STORIES Ovarian cancer The signs of ovarian cancer may not appear until the later stages. Find out if you're at risk. Office exercise: Add more activity to your workday Is an office job keeping you from exercising? From balancing on a fitness ball to adjusting your commute, try these tips to rev up your routine. EXPERT ANSWERS Natural remedies for depression: Are they effective? Herbal and dietary supplements for depression can't replace proper treatment. But some show promise. Cold or allergy: Which is it? Is your fall cold really a seasonal allergy? Learn the symptoms of each. PLUS ADDITIONAL HIGHLIGHTS Prediabetes Domestic violence against women: Recognize patterns, seek help Celiac disease Breakfast recipes Click here to get a free e-subscription to the Housecall newsletter.